Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2019 8
2020 15
2021 8
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. Loscocco GG, et al. Among authors: coltro g. Am J Hematol. 2024 Jan;99(1):68-78. doi: 10.1002/ajh.27136. Epub 2023 Oct 17. Am J Hematol. 2024. PMID: 37846894
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
Guglielmelli P, Maccari C, Sordi B, Balliu M, Atanasio A, Mannarelli C, Capecchi G, Sestini I, Coltro G, Loscocco GG, Rotunno G, Angori E, Borri FC, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: coltro g. Blood Cancer J. 2023 Jan 30;13(1):21. doi: 10.1038/s41408-023-00786-x. Blood Cancer J. 2023. PMID: 36710362 Free PMC article. No abstract available.
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
Coltro G, Sant'Antonio E, Palumbo GA, Mannelli F, De Stefano V, Ruggeri M, Elli EM, Zanotti R, Borsani O, Bertozzi I, Duminuco A, Betti S, Carli G, Cavalca F, Tanasi I, Rumi E, Randi ML, Garibaldi B, Loscocco GG, Guglielmelli P, Vannucchi AM. Coltro G, et al. Cancer Med. 2023 Apr;12(7):8166-8171. doi: 10.1002/cam4.5618. Epub 2023 Jan 27. Cancer Med. 2023. PMID: 36708083 Free PMC article.
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.
Loscocco GG, Guglielmelli P, Mannelli F, Mora B, Mannarelli C, Rotunno G, Pancani F, Maccari C, Bartalucci N, Romagnoli S, Coltro G, Passamonti F, Vannucchi AM. Loscocco GG, et al. Among authors: coltro g. Am J Hematol. 2022 Sep;97(9):E347-E349. doi: 10.1002/ajh.26648. Epub 2022 Jul 15. Am J Hematol. 2022. PMID: 35796725 Free article. No abstract available.
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.
Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Guglielmelli P, Vannucchi AM. Mannelli F, et al. Among authors: coltro g. Am J Hematol. 2022 Jul;97(7):846-855. doi: 10.1002/ajh.26548. Epub 2022 Mar 31. Am J Hematol. 2022. PMID: 35338671 Free PMC article.
38 results